nebentan
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 4, 2002 (NCT00048659)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Endothelin receptor ET-AANTAGONIST
EDNRA antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccccc1Oc1c(NS(=O)(=O)/C=C/c2ccccc2)nc(-c2ncccn2)nc1OC- Mol. weight
- 491.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107760 ↗
Also known as
- he 11
- he-11
- he-11
- he-11
- n-(6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl)-2-phenylethenesulfonamide
- nebentan
- nebentan
- nibentan
- n-mmpp-phenylethenesulfonamide
- ym598
- ym598
- ym598
- ym-598
- ym-598
- ym-598
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00050297 | Phase 2 | Dec 3, 2002 | Astellas |
| NCT00048659 | Phase 2 | Nov 4, 2002 | Astellas |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 2 | 2 | 1 | 2002 |
1 organizations
Page 1 / 1